Hormonal
Chronic low-grade inflammation is a causative mechanism for insulin resistance and metabolic disease in obesity, rather than merely a consequence.
If you are overweight, your body may be in a state of chronic, low-grade inflammation that actively interferes with how your cells respond to insulin. This isn't just 'being fat'; it's a biological shift that promotes metabolic disease. Addressing this requires looking beyond simple calorie counting to strategies that may reduce this inflammatory burden, such as improving diet quality and managing stress, as the inflammation itself drives insulin resistance.
recent insights suggest that it [inflammation] may play a causative role in generating insulin resistance, defective insulin secretion, and disruption of other aspects of energy homeostasis.
Why this rating
Based on a comprehensive review of multiple studies including knockout mice models and human correlations, though specific clinical trial outcomes are summarized rather than presented as primary data.
Source
Inflammatory mechanisms linking obesity and metabolic disease
Alan R. Saltiel et al. · Journal of Clinical Investigation · 2017
DOI 10.1172/jci92035
More from this paper
- Obesity-induced inflammation involves a shift in adipose tissue macrophages from an anti-inflammatory M2 state to a pro-inflammatory M1 state, which secretes cytokines like TNF-α that block insulin signaling.Good
- Inhibition of specific inflammatory signaling pathways (NF-κB and JNK) can disrupt the link between obesity and insulin resistance, suggesting these pathways are therapeutic targets.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →